-
-
-
-
-
-
-
Vitrolife AB (publ) Interim report Q1, 2025: Strong performance in EMEA
-
-
-
-
-
-
-
Vitrolife Group makes an impairment charge of SEK 4.3 billion relating to Igenomix and provides preliminary financials for the fourth quarter 2023
-
-
-
-
-
-
-
Vitrolife AB Interim report January-March 2022: Building on our strong growth momentum
-
-
-
-
-
-
1,199,896 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

